It is debatable whether the diagnostic value of the BTA stat test in detecting bladder cancer is superior to urine cytology.[sup.11]-[sup.17] To understand the nuances of the BTA test and the urine cytology test in diagnosis, we conducted a systematic review of published findings and used meta-analysis techniques to quantitatively combine results.
Extracted data included study details (e.g., the first author's name, research year of study, year of study publication, location of participants, design of studies, follow-up time) and patient characteristics (e.g., age, gender of patients with the BTA test and the cytology test, sample size).
A significant interaction was observed between exercise and medication use based on results of the BTA test
and the Digit Span Forward and Backward Task.
Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test. Eur Urol 1999;35:93-7.
Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder.
Because original BTA test sensitivity (approximately 40%) was no better than that of cytology, several assay modifications were introduced, including the BTA stat and BTA TRAK.
The newest BTA test (BTA TRAK) measures the levels of hCFHrp.
Cytological study of exfoliated cells in the urine is beneficial for the diagnosis and surveillance of high-grade disease, but is often normal and of limited value for low-and intermediate-grade tumours.[sup.3,4] A number of novel immunoassays for cancer-associated proteins in voided urine have been investigated as diagnostic tool to replace cytology, including BTA test, BTA Stat test, NMP22 and Immunocyt.[sup.5]-[sup.8] Most of these markers appear to have a greater sensitivity than cytology, especially for detecting lower grade tumours,[sup.9,10] although often at a cost of specificity.
Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer.
The use of the BTA Test
in the detection of persistent or recurrent transitional-cell cancer of the bladder.
Her fitness and BTA tests
were assessed at the Matt Roberts Centre, One Aldwych, London WC2 (020-7300 0600).